The approval and success of powerful new cancer treatments such as CAR T-cell therapy are breeding optimism among companies, scientists and patients around the world.TD2 can help influence your trial design and get your drug on a faster path to approval.
September 30, 2020
- How the FDA’s Plausible Mechanism Framework Signals the Future of Precision Oncology
- What Makes Radioligand Therapy IND Strategy Fundamentally Different?
- Receptor Mediated Therapies in the Clinic: From Targeting to Impact
- A Translational Lens on Synergistic Cancer Therapy: Insights from Our Recent Case Study
- Redesigning Preclinical Oncology: A Framework for Improving Clinical Translatability with AI, RECIST-Inspired Metrics, and Systems-Level Thinking
How the FDA’s Plausible Mechanism Framework Signals the Future of Precision Oncology
The FDA’s newly announced Plausible Mechanism Framework marks an important step toward aligning regulatory pathways with the realities of modern ...
What Makes Radioligand Therapy IND Strategy Fundamentally Different?
Your browser does not support the video tag.
Receptor Mediated Therapies in the Clinic: From Targeting to Impact
Your browser does not support the video tag. Receptor mediated therapies have fundamentally changed how cancer is treated in the clinic. What began ...
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
